Hypopituitarism, including growth hormone (GH) deficiency, is accompanied by increased morbidity and mortality. These factors may be due to the underlying disease and treatments such as surgery or radiotherapy, but can also arise from GH substitution therapy at nonphysiological doses. Nevertheless, emerging long-term data on GH replacement therapy now indicate benefits for bone health.
This is a preview of subscription content, log in via an institution to check access.
References
Elbornsson, M. et al. Fifteen years of growth hormone (GH) replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur. J. Endocrinol. http://dx.doi.org/10.1530/EJE-11-1072.
Giustina, A. Mazziotti, G. & Canalis, E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–539 (2008).
Holmer, H. et al. Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J. Bone Miner. Res. 22, 1842–1850 (2007).
Brixen, K. et al. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study. J. Bone Miner. Res. 10, 1865–1874 (1995).
Hansen, T. B. et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 81, 3352–3359 (1996).
Götherström, G., Bengtsson, B. A., Bosaeus, I., Johannsson, G. & Svensson, J. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur. J. Endocrinol. 156, 55–64 (2007).
Jørgensen, A. P. et al. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Horm. IGF Res. 21, 69–75 (2011).
Rubeck, K. Z. Bertelsen, S., Vestergaard, P. & Jørgensen, J. O. Impact of GH substitution on exercise capacity and muscle strength in GH-deficient adults: a meta-analysis of blinded, placebo-controlled trials. Clin. Endocrinol. (Oxf.) 71, 860–866 (2009).
Götherström, G. et al. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. J. Clin. Endocrinol. Metab. 94, 809–816 (2009).
Benito, M. et al. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J. Bone Miner. Res. 20, 1785–1791 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A. P. Jørgensen declares associations with the following companies: Novartis (speakers bureau), Novo Nordisk (speakers bureau; grant/research support), Merck Serono (speakers bureau; grant/research support), Pfizer (speakers bureau; grant/research support). J. Bollerslev declares he has received grant/research support from the following companies: Novartis, Novo Nordisk, Merck Serono, Pfizer.
Rights and permissions
About this article
Cite this article
Jørgensen, A., Bollerslev, J. Growth hormone replacement—implications for bone health. Nat Rev Endocrinol 8, 325–326 (2012). https://doi.org/10.1038/nrendo.2012.50
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2012.50
- Springer Nature Limited